Home > Healthcare > Pharmaceuticals > Pharma Manufacturing > Cardiovascular Clinical Trials Market

Cardiovascular Clinical Trials Market Share

Report ID: GMI7404
Published Date: Nov 2023
Report Format: PDF

Download Free Sample

Cardiovascular Clinical Trials Market Share

The leading market players are actively engaging in inorganic strategic measures, such as mergers, partnerships, and acquisitions, to bolster their presence in the cardiovascular industry. ICON plc, Charles River and IQVIA account for significant market share. These companies are prioritizing strategies like outsourcing and transitioning to CROs to boost capabilities, streamline operations, and navigate regulatory challenges.

The prominent market players operating in the cardiovascular clinical trials industry is as mentioned below:

Eli Lilly & Company
IQVIA Inc
Worldwide Clinical Trials
ICON plc
Thermo Fisher Scientific (PPD Inc)
Syneos Health
Medpace, Inc.
Veeda Clinical Research
WuXi AppTech
Pfizer
Merck & Co

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Cardiovascular clinical trials industry size was USD 5.1 billion in 2022 and is expected to reach USD 9.2 billion by 2032 due to the rising incidence of cardiovascular diseases, such as heart failure, stroke, and coronary artery diseases worldwide.

The phase III segment held 34.9% share of the cardiovascular clinical trials industry in 2022 and is expected to register appreciable CAGR from 2023-2032 on account of their pivotal role in evaluating treatment efficacy and safety before seeking regulatory approval.

North America cardiovascular clinical trials industry is expected to register 5.6% CAGR from 2023-2032 due to the presence of well-established CROs with expertise in cardiovascular clinical trials, including Worldwide Clinical Trials, ICON plc, Caidya, and several others in the region.

Eli Lilly & Company, IQVIA Inc, Worldwide Clinical Trials, ICON plc, Thermo Fisher Scientific (PPD Inc), Syneos Health, Medpace, Inc., Veeda Clinical Research, and WuXi AppTech are some of the major cardiovascular clinical trials companies worldwide.